Returning to academia after a career in big pharma

Transcription

1 Returning to academia after a career in big pharma Neil Carragher (n.carragher@ed.ac.uk) Edinburgh Cancer Discovery Unit (ECDU) (Est.2011) Edinburgh Phenotypic Assay Centre (E-PAC) (Est.2015) University of Edinburgh Edinburgh Cancer Research UK Centre MRC Institute of Genetics and Molecular Medicine

2 Topics 1. My Career Path: (Industry to Academia to Industry to Academia) 1. Working Industry Vs Academia (personal view!) 2. Life in Industry: Examples of Day-to-day responsibility 3. Life in Academia: Examples of Day-to-day responsibility 4. A changing world in Industry and Academia o Academic-Industry partnerships o Academic-Academic partnerships 1. New initiatives in academic training (University of Edinburgh) 1. Tips? & questions?

3 Career Path: University of Aberdeen: cell & immunobiology (1992) Academia Glengordon Knitwear Factory, Aberdeen (pom-poms) ( ) Industry +PhD Oxford ( ) University of Washington, Seattle ( ) (Dept of Pathology: Atherosclerosis) Academia Beatson Institute for Cancer Research ( ) Academia Advanced Science & Technology Lab ( ) Industry Edinburgh Cancer Research Centre UoE (2010 -?) Academia

4 Industry vs Academia Key words: Industry Milestones Timeline Career development Reward (bonus/promotion) Management Salary Meetings Academia Milestones! Timeline! Career development Reward? Management Teaching Salary Freedom Continuity (staff & funding) Meetings! Publications!

5 Line Management: 5 FTE (matrix management) Project Management: Associate Principal Scientist: AstraZeneca BAND D 1.Phenotypic Profiling: 5FTE, 1 contract, 1MSc (+4 collaborators Boston) (+external collaborators) 2. Functional Profiling: 2FTE (migration/invasion/angiogenesis) 3. In Vivo/Ex Vivo Imaging: 1FTE +external collaborators(1postdoc/1phd) (migration/invasion/angiogenesis) Day to day -Project management (Planning/Reporting) -Scoping, initiating and managing collaborations -Technology Evaluation (visits, alliances with vendors/academics) -Line Management -PR -Lab work

6 Line Management: 5 FTE Project Management: 1.Phenotypic Profiling: 4FTE, 1 contract, 1MSc (+4 collaborators Boston) (+external collaborators MIT) 2. Functional Profiling: 2FTE (migration/invasion/angiogenesis) 3. Drug combinations strategy: across all disease areas and all AstraZeneca sites. Manage core matrix team of 16 FTE & 3 external collaborations (multi-million dollar budget!) 4. Cancer strategy matrix team: Day to day Principal Scientist: AstraZeneca BAND E -Project management (Planning/Reporting) -Scoping, initiating and managing collaborations -Strategy, Continuous Improvement: productivity/performance/innovation -Technology Evaluation (visits, alliances with vendors/academics) -Line Management -PR -Lots of travel and Lab work no more!

7 Principal Investigator University of Edinburgh Start from bottom up: Laboratory space and 25,000 Line Management: 7 FTE (3 post doc; 3 Research assistants; 1 PhD studenship) Project Management: 1. 4 major industry collaboration 2. ERC phenotypic screening projects 3. Co-applicant and supervisor in large brain cancer program 4. Co-applicant and supervisor in pro-drug/chemical biology program Day to day -Project management (Planning/Reporting) -Scoping, initiating and managing collaborations -Technology Evaluation (visits, alliances with vendors/academics) -Line Management -PR (More publications and conference talks) -Occasional teaching, essay marking. -PhD studentship (second supervisor), Lab placements; Mentoring

8 Professor of Drug Discovery University of Edinburgh Principal Investigator responsibilities + New responsibilities: Head of Institute Biological Safety Committee Head of Institute Translation & Commercialization CSO Phenomics Discovery Initiative Director of the Edinburgh Cancer Discovery Unit Director of the Edinburgh Phenotypic Assay Centre School of Biological Sciences Research Committee College of Medicine/Vet Medicine Innovation Committee Cancer Research UK: Small molecule expert review panel New Agents Committee Advisory panel for CRUK Centre for Drug Development

9 ECDU: Western General College of Science & Engineering E-PAC: Royal infirmary

10 an opportunity for cross-disciplinary research integrated approach Interface between: Basic Research, Clinical research, Health Service & Industry smarter clinical trials better treatments basic biologists geneticists translational scientists chemists chemical biologists physicists filling the skills gap engineers computational biologists mathematicians pharmacologists clinician scientists phase 1 and phase 11 doctors surgeons pathologists NHS consultants comprehensive translational centre model of research and service

11 Acknowledgements Academic - Industry - Partnerships Poster 1015

12 Poster 1015 find out about joi Academia Public Private Partnership to develop innova ve, validated, phenotypic assays Access to world-class facili es Best in class compound library Needs defined by industry Human disease relevant assays Assays sourced from academia & clinic Risk and cost sharing model Wet diligence Access to precompe ve data Shared consor um data & knowledge Nego ated contract and annual fee Pharma Industry Founding industrial partner

13

14 Proposed: Industry Academic Fellowship Scheme

15 Tips: Innovation and up-to-date Embrace new approaches/technologies Broad skill set (adaptability) & Hard work = Motivated Competitive CV: Relevant skills, Relevant work experience, Publications, References Plan your training and your career path for your dream job: -Look at Job description of current advertised posts-if you do not have the skills required then seek training course/work experience Science more fun than making pom-poms!

16 Acknowledgements Acknowledgements ECDU/EPAC: Uni. of Edinburgh: Chemistry John Dawson Margaret Frame, David Gray Asier Unciti-Broceta Kenny Macleod Val Brunton Craig Fraser Dahlia Doughty-Shenton Alan Serrels Jason Weiss Ashraff Makda Bryan Serrels Alison Munro Steve Pollard, Paul Brennan Nils Lindstrom Dario Magnani Ida Niklasson Siddharthan Chandran Scott Warchal Duncan Sproul Hitesh Patel Guido Sanguinetti Paul Timpson NPSC: Andrew Hopkins; Paul Andrews; Daniel Ebner; Denise Barrault Carrick Therapeutics, Ltd. Centre for Drug Development